Research Highlights
Jeff Donovan

$3.95
Journal of the Dermatology Nurses' Association
February 2010 
Volume 2  Number 1
Pages 36 - 37
 
  PDF Version Available!

ABSTRACT
Von Hoff, D. D., LoRusso, P. M., Rudin, C. M., Reddy, J. C., Yaunch, R. L., Tibes R., et al. (2009). Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. New England Journal of Medicine, 361, 1164-1172.Basal cell carcinoma (BCC) is the most common skin cancer in the United States. Overall, most BCCs are readily curable. Metastatic BCC is uncommon but is associated with poor prognosis. The median survival is 8 months. Molecular studies have shown that many BCCs are associated with gene mutations in a cellular signaling pathway known as the hedgehog signaling pathway. These mutations send signals into cancer cells to instruct them to proliferate. The drug GDC-0449 is a specific inhibitor of one component of the hedgehog pathway.In this study, the authors evaluated the efficacy of GDC-0449 in the treatment of 15 patients with locally advanced BCC and 18 patients with metastatic BCC. Patients were followed for a median of 9.8 months. Of the 33 patients in the study, 18 showed benefit from treatment with GDC-0449. Two of these 18 patients had a complete response, and 16 had a partial response to the drug. Eleven patients did not demonstrate any increase in the size of their tumor during the treatment interval. In 4 patients, the tumor continued to grow despite GDC-0449. The drug was generally well tolerated, although side effects included fatigue (4 patients), hyponatremia (2 patients), muscle spasm (1 patient), and atrial fibrillation (1 patient).REMARK: It has long been recognized that the hedgehog pathway is important in the development of BCC. The oral drug GDC-0449 is an inhibitor of the hedgehog pathway and appears to have antitumor activity against locally advanced and metastatic BCC. Further studies will be helpful to determine how GDC-0449 can best be combined with other therapies to treat advanced disease. Moreover, one wonders whether a topical formulation of GDC-0449 could be designed and used in other less severe forms of BCC. It will be

Purchase Now !

To purchase this item, follow the instructions below. If you’re not already logged in, be sure to enter your login information below to ensure that your item is saved to your File Drawer after you purchase it.

Not a member? Join now for Free!


Cost:$3.95
1) If you're not already logged in, enter your information below to save this item in your File Drawer for future viewing.

User name:


Password


Forgot your user name or password?
2)  If you have a coupon or promotional code, enter it
here.(If not, just click Continue.


Digital Coupon: (optional)

3)  Click Continue to go to the next screen, where
you'll enter your payment details.






jQuery UI Accordion - Default functionality

For life-long learning and continuing professional development, come to Lippincott's NursingCenter.

Nursing Jobs Plus
Featured Jobs
Recommended CE Articles Recommended Nursing Articles

Meeting the Needs of Family Members of ICU Patients
Critical Care Nursing Quarterly, October/December 2014
Free access will expire on December 22, 2014.


Dealing with the specter of phantom limb pain
Nursing2014 , November 2014
Free access will expire on December 8, 2014.


The Power of Nursing Peer Review
JONA: Journal of Nursing Administration, November 2014
Free access will expire on December 8, 2014.


More Recommended Articles

Subscribe to Recommended Articles

Evidence Based Practice Skin Care Network NursingCenter Quick Links What’s Trending Events